Compounds > xr5944
Page last updated: 2024-12-08

xr5944

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

XR5944: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID439035
CHEMBL ID30424
SCHEMBL ID626969
MeSH IDM0398613

Synonyms (22)

Synonym
n,n'-(1,2-ethanediylbis(imino-2,1-ethanediyl))bis(9-methyl-1-phenazinecarboxamide)
1-phenazinecarboxamide, n,n'-(1,2-ethanediylbis(imino-2,1-ethanediyl))bis(9-methyl-
xr 5944
CHEMBL30424
9-methyl-n-[2-[2-[2-[(9-methylphenazine-1-carbonyl)amino]ethylamino]ethylamino]ethyl]phenazine-1-carboxamide
343247-32-5
unii-ljh9xg66q9
ljh9xg66q9 ,
mln 944
SCHEMBL626969
xr-5944
DTXSID10187891
mln-944
xr5944
DB06364
1-phenazinecarboxamide, n,n'-[1,2-ethanediylbis(imino-2,1-ethanediyl)]bis[9-methyl-
n,no bis[2-(9-methylphenazine-1-carboxamido)ethyl]-1,2-ethanediamine
nsc-754366
nsc754366
xr-5944.14
9-methyl-n-(2-(2-(2-((9-methylphenazine-1-carbonyl)amino)ethylamino)ethylamino)ethyl)phenazine-1-carboxamide
AKOS040754470

Research Excerpts

Overview

XR5944 is a DNA-targeted agent with exceptionally potent antitumor activity. It has a novel DNA binding mode, bis-intercalation and major groove binding, as well as a novel mechanism of action, transcription inhibition.

ExcerptReferenceRelevance
"XR5944 is a DNA-targeted agent with exceptionally potent antitumor activity and a novel DNA binding mode, bis-intercalation and major groove binding, as well as a novel mechanism of action, transcription inhibition."( Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug-Design and Mechanism of Action.
Buric, AJ; Dickerhoff, J; Yang, D, 2021)		1.64
"XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. "( DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944.
Lin, C; Yang, D, 2015)		2.1
"XR5944 (MLN944) is a novel DNA targeting agent with potent antitumor activity, both in vitro and in vivo, against several murine and human tumor models. "( The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.
Charlton, PA; Cree, IA; Di Nicolantonio, F; Knight, LA; Mercer, SJ; Norris, D; Sharma, S; Whitehouse, PA, 2004)		2.05
"XR5944 (MLN944) is a novel bis-phenazine currently in phase I clinical trials that has demonstrated potent cytotoxic activity against a variety of tumor models. "( Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma.
Brown, JL; Charlton, PA; Harris, SM; Mistry, P; Scott, JA, 2005)		2.05

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis was performed during the first cycle of treatment and plasma was assayed for XR5944."( First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action.
Bissett, D; Cooper, M; Rankin, EM; Steiner, J; Thomas, H; Verborg, W; Waterfall, J, 2007)		0.81

Compound-Compound Interactions

ExcerptReferenceRelevance
" In the present study, the antitumour activity of XR5944 was investigated in combination with 5-fluorouracil (5-FU) or irinotecan in human colon carcinoma cell lines and xenografts."( Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
Brown, JL; Charlton, PA; Freathy, C; Harris, SM; Mistry, P, 2005)		0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID42556Inhibitory concentration required to reduce cell growth to 50% of control cultures in the CAK1 human cell line2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID105658Inhibitory concentration of the drug resulting in inhibition of cell growth to 50% of controls in MOLT-4 (human leukemia)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID84645Inhibitory concentration required to reduce cell growth to 50% of control cultures in the HTC116 human cell line2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID131980In vivo activity in HT-29 model for tumor growth delay after i.p. administration of 13.3 mg/kg in C57/B1 mice2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID100105Inhibitory concentration required to reduce cell number to 50% of control cultures in LL(Lewis lung carcinoma cell line)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID37879Concentration of the drug to reduce cell number to 50% of controls in AuxB1 cell line2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID226440Average GI50 value for the drug over the whole cell line panel2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID55576Concentration of the drug to reduce cell number to 50% of controls in D3F cell line2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID91918Inhibitory concentration required to reduce cell number to 50% of control cultures in JLc(Jurkat human leukemia)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID229538Ratio of IC50 values obtained from Jurkat lines, (JLa /JLc)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID131982In vivo activity in colon 38 model for tumor growth delay after i.p. administration of 13.3 mg/kg in C57/B1 mice2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID202998Inhibitory concentration required to reduce cell growth to 50% of control cultures in the SKOV3 human cell line2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID229536Ratio of IC50 values obtained from CHrC5 and AuxB1 cell lines2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID150951Inhibitory concentration required to reduce cell number to 50% of control cultures in P388 (murine leukemia cell line)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID131983In vivo activity in colon 38 model for tumor growth delay after i.p. administration of 20 mg/kg in C57/B1 mice2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID214410Inhibitory concentration of the drug resulting in inhibition of cell growth to 50% of controls in U937 (human leukemia)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID103400Inhibitory concentration required to reduce cell growth to 50% of control cultures in the MCF-7 human cell line2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID84285Inhibitory concentration required to reduce cell growth to 50% of control cultures in the HT-29 human cell line2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID229537Ratio of IC50 values obtained from D3F-C10 and D3F cell lines2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID229539Ratio of IC50 values obtained from Jurkat lines, (JLd /JLc)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID131985In vivo activity in colon 38 model for tumor growth delay after i.p. administration of 8.9 mg/kg in C57/B1 mice2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID144811Inhibitory concentration required to reduce cell growth to 50% of control cultures in the NCI-ADR human cell line2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
AID85759Inhibitory concentration of the drug resulting in inhibition of cell growth to 50% of controls in HT-29 (human colon)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (61.11)29.6817
2010's4 (22.22)24.3611
2020's3 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.51 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.56%)5.53%
Reviews2 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		7.0210nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.7230delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
etoposide
[no description available]		2.4220beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		210pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
irinotecan
[no description available]		7.4220carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
phenazine-1-carboxamide
phenazine-1-carboxamide: used as a root colonization. phenazine-1-carboxamide : An aromatic amide that is phenazine substituted at C-1 with a carbamoyl group.		2.110aromatic amide;
monocarboxylic acid amide;
phenazines
carboplatin
[no description available]		7.0210
elinafide
elinafide: structure given in first source		210
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		2.4320actinomycinmutagen
oligonucleotides
[no description available]		2.110
guanosine triphosphate
Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.		2.3110guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		05.0631
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		05.0631
Breast Cancer
[description not available]		02.0510
Colorectal Cancer
[description not available]		02.0510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0510
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0510
Experimental Neoplasms
[description not available]		02.0210
Cancer of Colon
[description not available]		02.4220
Colonic Neoplasms
Tumors or cancer of the COLON.		02.4220
Carcinoma, Non-Small Cell Lung
[description not available]		02.4220
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.4220
Cancer of Lung
[description not available]		0210
Lung Neoplasms
Tumors or cancer of the LUNG.		0210